https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2823%2901796-8/fulltext
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial - The Lancet